| Neuron-specific enolase as a biomarker: biochemical and clinical aspects MA Isgrò, P Bottoni, R Scatena Advances in cancer biomarkers: from biochemistry to clinic for a critical …, 2015 | 567 | 2015 |
| CA 19-9: biochemical and clinical aspects S Scarà, P Bottoni, R Scatena Advances in Cancer Biomarkers: From biochemistry to clinic for a critical …, 2015 | 324 | 2015 |
| The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic R Scatena, P Bottoni, G Botta, GE Martorana, B Giardina American journal of physiology-cell physiology 293 (1), C12-C21, 2007 | 230 | 2007 |
| The role of CA 125 as tumor marker: biochemical and clinical aspects P Bottoni, R Scatena Advances in Cancer Biomarkers: From biochemistry to clinic for a critical …, 2015 | 227 | 2015 |
| Glycolytic enzyme inhibitors in cancer treatment R Scatena, P Bottoni, A Pontoglio, L Mastrototaro, B Giardina Expert opinion on investigational drugs 17 (10), 1533-1545, 2008 | 203 | 2008 |
| Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks R Scatena, P Bottoni, A Pontoglio, B Giardina Current medicinal chemistry 17 (1), 61-73, 2010 | 107 | 2010 |
| 3-(4-Aroyl-1-methyl-1 H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or-C4 substitutions on … A Mai, S Massa, I Cerbara, S Valente, R Ragno, P Bottoni, R Scatena, ... Journal of medicinal chemistry 47 (5), 1098-1109, 2004 | 94 | 2004 |
| Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential R Scatena, P Bottoni, GE Martorana, B Giardina Expert opinion on investigational drugs 14 (7), 835-846, 2005 | 93 | 2005 |
| 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through … R Ragno, A Mai, S Massa, I Cerbara, S Valente, P Bottoni, R Scatena, ... Journal of medicinal chemistry 47 (6), 1351-1359, 2004 | 88 | 2004 |
| Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications R Scatena, P Bottoni, GE Martorana, F Ferrari, P De Sole, C Rossi, ... Biochemical and Biophysical Research Communications 319 (3), 967-973, 2004 | 80 | 2004 |
| An update on pharmacological approaches to neurodegenerative diseases R Scatena, GE Martorana, P Bottoni, G Botta, P Pastore, B Giardina Expert opinion on investigational drugs 16 (1), 59-72, 2007 | 74 | 2007 |
| Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key? R Scatena, P Bottoni, B Giardina PPAR research 2008, 2008 | 56 | 2008 |
| Circulating tumour cells and cancer stem cells: a role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical … R Scatena, P Bottoni, B Giardina Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1835 (2), 129-143, 2013 | 55 | 2013 |
| Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates A Mai, S Massa, D Rotili, R Pezzi, P Bottoni, R Scatena, J Meraner, ... Bioorganic & medicinal chemistry letters 15 (21), 4656-4661, 2005 | 55 | 2005 |
| Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator R Scatena, P Bottoni, F Vincenzoni, I Messana, GE Martorana, G Nocca, ... Chemical research in toxicology 16 (11), 1440-1447, 2003 | 51 | 2003 |
| Cancer stem cells: the development of new cancer therapeutics R Scatena, P Bottoni, A Pontoglio, B Giardina Expert opinion on biological therapy 11 (7), 875-892, 2011 | 49 | 2011 |
| Advances in mitochondrial medicine R Scatena, P Bottoni, B Giardina Springer Science & Business Media, 2012 | 48* | 2012 |
| Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs) R Scatena, G Martorana, P Bottoni, B Giardina IUBMB life 56 (8), 477-482, 2004 | 44 | 2004 |
| Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy R Scatena, P Bottoni, A Pontoglio, B Giardina PROTEOMICS–Clinical Applications 4 (2), 143-158, 2010 | 43 | 2010 |
| Bezafibrate as differentiating factor of human myeloid leukemia cells R Scatena, G Nocca, P De Sole, C Rumi, P Puggioni, F Remiddi, ... Cell Death & Differentiation 6 (8), 781-787, 1999 | 41 | 1999 |
